Division of Immunology, Department of Biology, University of Konstanz, Universitätsstrasse 10, D-78457 Konstanz, Germany.
Curr Opin Immunol. 2013 Feb;25(1):74-80. doi: 10.1016/j.coi.2012.11.004. Epub 2012 Dec 6.
Treatment of cells with interferon-γ leads to the replacement of the constitutive catalytic proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i), and LMP7 (β5i), respectively, building the so-called immunoproteasome. The incorporation of these subunits is required for the production of numerous MHC class-I restricted T cell epitopes. Recently, new evidence for an involvement of the immunoproteasome in other facets of the immune response emerged. Investigations of autoimmune diseases in animal models and a genetic predisposition of β5i in human autoimmune disorders suggest a crucial function of the immunoproteasome in proinflammatory diseases. The recent elucidation of the high-resolution structure of the immunoproteasome will facilitate the design of immunoproteasome selective inhibitors for pharmacological intervention.
用干扰素-γ处理细胞会导致组成性催化蛋白酶体亚基β1、β2 和β5 分别被诱导性亚基 LMP2(β1i)、MECL-1(β2i)和 LMP7(β5i)取代,形成所谓的免疫蛋白酶体。这些亚基的掺入对于产生许多 MHC Ⅰ类限制的 T 细胞表位是必需的。最近,免疫蛋白酶体在免疫反应的其他方面的参与有了新的证据。在动物模型中的自身免疫性疾病的研究和人类自身免疫性疾病中β5i 的遗传易感性表明,免疫蛋白酶体在促炎疾病中具有关键作用。免疫蛋白酶体的高分辨率结构的最新阐明将有助于设计免疫蛋白酶体选择性抑制剂进行药理学干预。